Redeye strongly reiterates its positive stance on Calliditas, a high-quality biotech whose longer-term blockbuster potential should be highlighted this autumn by positive Phase III trial data for its key drug Nefecon. The recent sentiment-driven downturn has pushed the share into bear territory that underestimates Nefecon’s decent likelihood of launch.
Read more and download the analysis: https://bit.ly/2UmXnff
Start following companies at Redeye to recieve the latest equity research within Life Science and Technology.
This is a press release from Redeye – Research Powered Investment Banking. https://www.redeye.se/about/